| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/25/2002 | WO2002032902A1 3,8-diazabicyclo[3.2.1]octanes and their use in the treatment of cardiac arrhythmias |
| 04/25/2002 | WO2002032901A2 Bridged piperazine derivatives |
| 04/25/2002 | WO2002032900A2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents |
| 04/25/2002 | WO2002032897A1 Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists |
| 04/25/2002 | WO2002032896A1 Furazanyl-triazole derivates for the treatment of diseases |
| 04/25/2002 | WO2002032894A1 Substituted imidazoles useful in the treatment of inflammatory diseases |
| 04/25/2002 | WO2002032893A2 Piperidine compounds as anti-allergic |
| 04/25/2002 | WO2002032889A1 Aromatic and heterocyclic thiazolyl thiourea compounds and use |
| 04/25/2002 | WO2002032881A1 Novel remedies or preventives for angiostenosis |
| 04/25/2002 | WO2002032880A1 New derivatives of cyano-aryl (or cyanoheteroaryl)-carbonyl-piperazinyl-pyrimidines, their preparation and application as medication |
| 04/25/2002 | WO2002032879A1 Dihydropyrimidine derivatives as cysteine protease inhibitors |
| 04/25/2002 | WO2002032876A2 Novel m-amino-phenylimino-imidazolidine derivatives for treating urinary incontinence |
| 04/25/2002 | WO2002032874A2 Substituted heterocyclic compounds for treating multidrug resistance |
| 04/25/2002 | WO2002032872A1 Nitrogenous aromatic ring compounds |
| 04/25/2002 | WO2002032869A2 Substituted heterocyclic compounds for treating multidrug resistance |
| 04/25/2002 | WO2002032868A2 2-substituted heterocyclic compounds and their use in treating multidrug resistance |
| 04/25/2002 | WO2002032867A1 Chemical compounds |
| 04/25/2002 | WO2002032864A1 Pharmaceutically active sulfanilide derivatives |
| 04/25/2002 | WO2002032862A2 Use of p38 inhibitors for the treatment of smoke inhalation |
| 04/25/2002 | WO2002032861A2 Orally active salts with tyrosine kinase activity |
| 04/25/2002 | WO2002032858A1 Cycloalkylfluorosulfonamide derivatives |
| 04/25/2002 | WO2002032857A1 Methods of producing oxazolidinone compounds |
| 04/25/2002 | WO2002032842A2 Compounds with high monoamine transporter affinity |
| 04/25/2002 | WO2002032507A1 7-amino-2-alkylthiopteridin-4-yl-amines for the treatment of chemokine-related diseases |
| 04/25/2002 | WO2002032460A1 Use of biologically degradable substituted hydrocarbons, the esters, ethers and /or amides thereof for prophylaxis of allergic inhalation reactions and/or for treatment of the nasal mucosa |
| 04/25/2002 | WO2002032459A2 Method of increasing the efficacy of antibiotics by complexing with cyclodextrins |
| 04/25/2002 | WO2002032456A1 Remedies or preventives for rheumatoid arthritis |
| 04/25/2002 | WO2002032443A1 Saururus chinensis extract for prevention and treatment of neurodegenerative disease |
| 04/25/2002 | WO2002032435A2 A composition including a platelet activating factor inhibitor and an antioxidant which interferes with the arachidonic acid cascade |
| 04/25/2002 | WO2002032434A1 S-adenosylmethionine and derivatives thereof for the treatment and prevention of alzheimer"s disease |
| 04/25/2002 | WO2002032433A1 Drug delivery system |
| 04/25/2002 | WO2002032432A1 Use of antiprogestins for the induction of apoptosis in a cell |
| 04/25/2002 | WO2002032431A1 Compositions for external preparations |
| 04/25/2002 | WO2002032430A1 Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases |
| 04/25/2002 | WO2002032429A2 Use of inhibitors of progesterone receptor for treating cancer |
| 04/25/2002 | WO2002032428A1 Oral formulation comprising an inhibitor compound of the ileal bile transport and an hmg co-a reductase inhibitor |
| 04/25/2002 | WO2002032427A1 Stable oral formulation containing benzimidazole derivative |
| 04/25/2002 | WO2002032426A1 Further improvements in and relating to the control of coccidia |
| 04/25/2002 | WO2002032425A2 Stable oral formulation containing benzimidazole derivative |
| 04/25/2002 | WO2002032424A1 Stable compositions of oxapenem-3-carboxylic acids by co-lyophilisation with pharmaceutical carriers |
| 04/25/2002 | WO2002032423A1 Pharmaceutical compositions containing oxapenem-3-carboxylic acids |
| 04/25/2002 | WO2002032422A2 Ep4 receptor inhibitors to treat rheumatoid arthritis |
| 04/25/2002 | WO2002032421A1 Indole compounds as minimally physiologial function monitioring agents |
| 04/25/2002 | WO2002032420A1 Method for producing an extract from cannabis plant matter, containing a tetrahydrocannabinol and a cannabidiol and cannabis extracts |
| 04/25/2002 | WO2002032419A2 Methods for modulating bladder function |
| 04/25/2002 | WO2002032418A1 Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis |
| 04/25/2002 | WO2002032417A1 Pharmaceutical preparations containing a dibenzocyclooctane lignan derivative for prevention and treatment of neurodegenerative disease |
| 04/25/2002 | WO2002032416A2 Inhibition of emetic effect of metformin with 5-ht3 receptor antagonists |
| 04/25/2002 | WO2002032415A2 Process of making and method of use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa cells |
| 04/25/2002 | WO2002032414A2 Ribavirin-pegylated interferon alfa hcv combination therapy |
| 04/25/2002 | WO2002032412A2 Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders |
| 04/25/2002 | WO2002032411A2 Combination of statins and sorbitol dehydrogenase inhibitors |
| 04/25/2002 | WO2002032410A2 Pharmaceutical composition comprising resveratrol for treating inflammatory respiratory disorders |
| 04/25/2002 | WO2002032409A2 Use of compound in the manufacture of a pharmaceutical for inhibiting steroid sulphatase and steroid dehydrogenase activity |
| 04/25/2002 | WO2002032408A2 Combinations of a thyromimetic compound and a statin |
| 04/25/2002 | WO2002032407A2 Use of hyaluronic acid derivatives for the prevention of inflammatory arthritis |
| 04/25/2002 | WO2002032406A2 Methods and products related to pulmonary delivery of polysaccharides |
| 04/25/2002 | WO2002032404A2 Nanoparticles |
| 04/25/2002 | WO2002032403A1 Medicinal compositions quickly disintegrating in the oral cavity and process for producing the same |
| 04/25/2002 | WO2002032401A1 Amifostine powder injection and its method of process |
| 04/25/2002 | WO2002032400A1 Liposomal formulation of mitoxantrone |
| 04/25/2002 | WO2002032399A1 Taxol liposome composition for treatment of cancer and preparation thereof |
| 04/25/2002 | WO2002032397A2 Electroprocessing in drug delivery and cell encapsulation |
| 04/25/2002 | WO2002032389A1 Method of treating stroke |
| 04/25/2002 | WO2002032387A1 Use of olive oil in the preparation of a product for oral hygiene for eliminating or reducing bacterial plaque and/or bacteria in the mouth |
| 04/25/2002 | WO2002032377A2 Estrogen receptor modulators |
| 04/25/2002 | WO2002032374A2 Methods for treating il-18 mediated disorders |
| 04/25/2002 | WO2002032373A2 Estrogen receptor modulators |
| 04/25/2002 | WO2002032285A2 Hydrophilic light absorbing compositions for determination of physiological function in critically ill patients |
| 04/25/2002 | WO2002032234A1 Anti-stress composition designed to be mainly incorporated in nutritional carriers |
| 04/25/2002 | WO2002032233A2 Treatment and prophylaxis of diseases and infections of pigs and poultry with aivlosin |
| 04/25/2002 | WO2002022112A9 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 04/25/2002 | WO2002010191A3 Immunomodulatory compounds |
| 04/25/2002 | WO2002010137A3 Indazole derivatives as JNK inhibitors |
| 04/25/2002 | WO2002009684A3 ERBB-2 selective small molecule kinase inhibitors |
| 04/25/2002 | WO2002002128A3 Oral compositions comprising antimicrobial agents |
| 04/25/2002 | WO2001097810A3 Use of therapeutic benzamide derivatives |
| 04/25/2002 | WO2001093847A3 Compositions, kits, and methods for promoting defined health benefits |
| 04/25/2002 | WO2001093833A3 Kits and methods for optimizing the efficacy of chondroprotective compositions |
| 04/25/2002 | WO2001093832A3 Aqueous chondroprotective compositions having defined dosage requirements for efficacious delivery |
| 04/25/2002 | WO2001093831A3 Low carbohydrate compositions, kits thereof, and methods of use |
| 04/25/2002 | WO2001089500A3 Agents and methods for increasing brain chaperonin levels |
| 04/25/2002 | WO2001089496A3 Compositions and methods for treating otic, ophthalmic and nasal infections comprising quinolone antibiotics |
| 04/25/2002 | WO2001087305A3 Method for treating functional dyspepsia using alosetron |
| 04/25/2002 | WO2001087283A3 New use of citreamicins |
| 04/25/2002 | WO2001083740A3 Splice-region antisense composition and method |
| 04/25/2002 | WO2001083440A3 Synthesis and use of thienotriazolodiazepines |
| 04/25/2002 | WO2001082874A3 A medicinal aerosol formulation |
| 04/25/2002 | WO2001081341A3 9-oxa-epothilon derivatives, method for the production and use thereof in pharmaceutical preparations |
| 04/25/2002 | WO2001081333A3 Regioselective synthesis of 3,4-di(carbocyclyl or heterocyclyl)thiophenes |
| 04/25/2002 | WO2001078698A3 Use of ngf-antagonists for the prevention or treatment of chronic visceral pain |
| 04/25/2002 | WO2001076574A3 Novel medical use of aldosterone synthase inhibitors alone or in combination with at1-receptor antagonists |
| 04/25/2002 | WO2001070208A3 Hormone replacement therapy using a combination of conjugated estrogens and medroxyprogesterone acetate |
| 04/25/2002 | WO2001066110A3 METHOD FOR THE TREATMENT OF RENAL DYSFUNCTION WITH sPLA2 INHIBITORS |
| 04/25/2002 | WO2001064205A3 Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor |
| 04/25/2002 | WO2001062300A3 Caspase activated prodrugs therapy |
| 04/25/2002 | WO2001062222A3 Cosmetic composition, especially for use on aging and/or stressed skin |
| 04/25/2002 | WO2001060975A3 Gene disruption methodologies in fungi for drug target discovery |
| 04/25/2002 | WO2001060847A3 avirulent, immunogenic flavivirus chimeras |
| 04/25/2002 | WO2001060174A3 Weight loss induced by reduction in neuropeptide y level |